ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/API/Cyclo(Arg-Gly-Asp-D-Phe-Val)
C26H38N8O7
574.6 g/mol
API

Cyclo(Arg-Gly-Asp-D-Phe-Val)

CAS137813-35-5
Category
API
Compound Class
Peptide
Primary Use
Pharmaceutical Raw Material

Cilengitide is a cyclic peptide based on the sequence cyclo(Arg-Gly-Asp-D-Phe-Val), designed as a research compound for studying αv integrins. It is primarily investigated for its role in angiogenesis and tumor biology, particularly in the context of glioblastoma research.

research reagent for αv integrin studiescompound for angiogenesis researchlaboratory tool in glioblastoma studies

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing Cyclo(Arg-Gly-Asp-D-Phe-Val)?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

SimilarStructure SimilarSimilarity 0.80

Cyclo(RGDfC)

CAS862772-11-0

research compound

SimilarStructure SimilarSimilarity 0.78

Cyclic RGDFK peptide

CAS161552-03-0

research compound

SimilarStructure SimilarSimilarity 0.77

Cilengitide

CAS188968-51-6

research reagent

ReferenceSame Category

Alintegimod

CAS1378535-08-0

pharmaceutical raw material

ReferenceSame Category

Valsartan

CAS137862-53-4

pharmaceutical raw material

ReferenceSame Category

Alanine Valsartan

CAS137862-57-8

pharmaceutical raw material

ReferenceSame Category

D-valsartan

CAS137862-87-4

pharmaceutical raw material

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more
Identifiers
IUPAC Name

2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid

InChIKey

YYQUWEHEBOMRPH-NYUBLWNDSA-N

SMILES

CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N

Synonyms (7)
  • c(RGDfV)
  • cyclo(Arg-Gly-Asp-D-Phe-Val)

Sourcing Cyclo(Arg-Gly-Asp-D-Phe-Val)?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→